BioCryst Pharmaceuticals Inc. (BCRX)

2.59
NASDAQ : Health Technology
Prev Close 2.58
Day Low/High 2.55 / 2.63
52 Wk Low/High 2.54 / 9.95
Avg Volume 2.36M
Exchange NASDAQ
Shares Outstanding 110.44M
Market Cap 284.93M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
BioCryst Initiates A Phase 2b Study Of BCX4208 As Add-on Therapy In Gout Patients Not Responding To Allopurinol Alone

BioCryst Initiates A Phase 2b Study Of BCX4208 As Add-on Therapy In Gout Patients Not Responding To Allopurinol Alone

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced the initiation of a Phase 2b study of BCX4208 as add-on therapy in gout patients who have not responded to allopurinol therapy alone.

BioCryst Reports New Data From Its Phase 2 Forodesine Study In Patients With Chronic Lymphocytic Leukemia At The 52nd Annual American Society Of Hematology Meeting

BioCryst Reports New Data From Its Phase 2 Forodesine Study In Patients With Chronic Lymphocytic Leukemia At The 52nd Annual American Society Of Hematology Meeting

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced the presentation of new data that confirms forodesine’s clinical activity in the treatment of chronic lymphocytic leukemia (CLL) at the 52 nd Annual...

BioCryst To Present New Data For BCX4208 Monotherapy At The 74th Annual American College Of Rheumatology (ACR) Scientific Meeting

BioCryst To Present New Data For BCX4208 Monotherapy At The 74th Annual American College Of Rheumatology (ACR) Scientific Meeting

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced the presentation of new data related to the efficacy and safety of BCX4208 for the treatment of gout at the 74 th ACR Scientific Meeting being held in...

BioCryst Awarded $1.1 Million In Grants For Qualifying Therapeutic Development Projects

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced that the Company had been awarded $1.

BioCryst Reports Third Quarter 2010 Financial Results And Provides Corporate Update

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the third quarter and nine months ended September 30, 2010.

BioCryst’s Partner Shionogi Receives Approval For Pediatric Use Of Peramivir In Japan

BioCryst’s Partner Shionogi Receives Approval For Pediatric Use Of Peramivir In Japan

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its partner, Shionogi & Co.

BioCryst To Present At Oppenheimer Healthcare Conference

BioCryst To Present At Oppenheimer Healthcare Conference

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced that Stuart Grant, Senior Vice President and Chief Financial Officer of BioCryst, plans to provide a corporate summary and update regarding its clinical...

BioCryst To Present New Clinical & Virologic Data For I.V. Peramivir At The 48th Annual IDSA Meeting

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced the presentation of data related to intravenous (i.

BioCryst Ranked Number Five In Deloitte’s 2010 Technology Fast 500™ Program For Fastest Growing Companies In North America

BioCryst Pharmaceuticals (NASDAQ:BCRX) today announced that it has been named number five on Deloitte’s 2010 Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life ...

BioCryst Pharmaceuticals To Announce Third Quarter 2010 Financial Results On October 28, 2010

BioCryst Pharmaceuticals (NASDAQ:BCRX) today announced that its third quarter 2010 financial results will be released on Thursday, October 28, 2010.

Biotech Stock Mailbag: Vivus

Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.

BioCryst Tripped Up by Downgrade

BioCryst Tripped Up by Downgrade

BioCryst shares slumped on heavy volume after the Birmingham, Ala.-based drug developer was hit with a downgrade.

BioCryst To Present At JMP Securities Healthcare Conference

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced that Dr.

BioCryst Reports Positive Results From A Phase 2 Study Of BCX4208 Combined With Allopurinol In Patients With Gout

BioCryst Reports Positive Results From A Phase 2 Study Of BCX4208 Combined With Allopurinol In Patients With Gout

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced positive top-line results from its randomized, double-blind, multi-center, placebo-controlled Phase 2 study designed to evaluate the urate-lowering activity...

BioCryst To Present Peramivir Data At The 50th Annual ICAAC Meeting

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced the presentation of data related to intravenous (i.

BioCryst Reports Results From Two Forodesine Oncology Studies

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced preliminary top-line results from its multinational, open-label, single-arm trial evaluating 200 mg once-daily oral forodesine in the treatment of relapsed...

Savient: Drug Approval or Another Delay?

Savient awaits word from FDA on the approval of its gout drug next week, but another delay is possible.

BioCryst To Host & Webcast Investor Day On September 16, 2010

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced that it will host and webcast its Investor Day in New York City on Thursday, September 16, 2010 from 9 a.

Biotech Calendar: Key Dates for September

Here's a list of September's potentially stock-moving biotech events

BioCryst’s Partner Green Cross Receives Marketing & Manufacturing Approval For Peramivir In South Korea

BioCryst’s Partner Green Cross Receives Marketing & Manufacturing Approval For Peramivir In South Korea

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced that its partner, Green Cross Corporation has received marketing and manufacturing approval from KFDA (Korean Food & Drug Administration) for ...

BioCryst Reports Second Quarter 2010 Financial Results And Provides Corporate Update

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced financial results for the second quarter and six months ended June 30, 2010.

BioCryst Pharmaceuticals To Announce Second Quarter 2010 Financial Results On August 5, 2010

BioCryst Pharmaceuticals (NASDAQ:BCRX) today announced that its second quarter 2010 financial results will be released on Thursday, August 5, 2010.

BioCryst Initiates A Phase 2 Study Of BCX4208 Alone And In Combination With Allopurinol In Patients With Gout

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced it is initiating a Phase 2 study of BCX4208 alone and in combination with allopurinol in patients with gout.

BioCryst To Present At Jefferies 2010 Global Life Sciences Conference

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced that Stuart Grant, Senior Vice President and Chief Financial Officer of BioCryst, plans to provide a corporate summary and updates regarding its clinical...

BioCryst Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript

BioCryst Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript

BioCryst Reports First Quarter 2010 Financial Results And Provides Corporate Update

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced financial results for the quarter ended March 31, 2010.

BioCryst Reports Positive Results From Part One Of Its Phase 2a Study Of BCX4208 In Patients With Gout

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced positive top-line results from a planned interim analysis of its ongoing Phase 2a, randomized, double-blind, placebo-controlled study to evaluate the ...

Demand for BioCryst Flu Drug Still Low: BioBuzz

The U.S. government still has a vast majority of its peramivir stockpile in place as H1N1 flu season comes to a close.

Cramer's 'Mad Money' Recap: Market Trumping Bearish Chatter (Final)

Cramer says the rally is for real and long term to the consternation of naysayers who have tried to put it down with horror stories.

'Mad Money Lightning Round': Get in on FLIR Systems

Cramer says investors need to hold on to this domestic-security play.

TheStreet Quant Rating: D- (Sell)